Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion to Participate in The 2026 Citizens Life Sciences Conference
08:00am, Wednesday, 18'th Feb 2026
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11,
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolve
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of “Moderate Buy” from Analysts
03:33am, Monday, 16'th Feb 2026
Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat Ratings
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Wednesday, 11'th Feb 2026
ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under E
Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:35pm, Wednesday, 14'th Jan 2026
Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
06:00pm, Sunday, 11'th Jan 2026
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up – Here’s What Happened
02:27am, Sunday, 04'th Jan 2026
Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $3.70, but opened at $3.86. Esperion Therapeutics shares l
Stock Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)
01:29am, Tuesday, 16'th Dec 2025
Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 10,363 call options on the company. This is an increase of 2
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Tuesday, 09'th Dec 2025
ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchas
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of “Moderate Buy” by Brokerages
03:34am, Wednesday, 03'rd Dec 2025
Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are presently covering the stock, Marketbeat.
Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript
04:03pm, Thursday, 20'th Nov 2025
Esperion Therapeutics, Inc. ( ESPR ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:00 AM EST Company Participants Benjamin Halladay - Chief Financial Officer Conference Call Particip
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercializa
Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors
10:16am, Wednesday, 12'th Nov 2025
Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide rang
Esperion Therapeutics, Inc. ( ESPR ) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST Company Participants Sheldon Koen
Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability
07:24am, Monday, 10'th Nov 2025
Esperion Therapeutics remains a buy despite market skepticism, recent stock offering, and underwhelming Q3 earnings, supported by strong cardiovascular drug franchises. ESPR's profitability timeline i
